CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 640 enrolled / 640 target
Drug / intervention
Sodium bicarbonate infusiondrug
Likely dose
Sodium bicarbonate infusion 125mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04010630
NCT04010630N/ACompletedHigh Momentum (7.9/mo)Completion was 30mo ago

Sodium Bicarbonate for the Treatment of Severe Metabolic Acidosis With Moderate or Severe Acute Kidney Injury in the Critically Ill: a Randomized Clinical Trial

University Hospital, Montpellier·interventional·Posted Jul 8, 2019·Updated Jun 15, 2026

In Brief

A clinical study evaluating Sodium bicarbonate infusion for Metabolic Acidosis and Acute Kidney Injury. Completed, enrolled 640 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

Severe metabolic acidemia in the critically ill (pH equal or less than 7.20; PaCO2 equal or less than 45mmHg and bicarbonate concentration equal or less than of 20 mmol/l) is associated with a 50% rate of day 28 mortality. Moderate to severe acute kidney injury is a frequent cause of metabolic acidemia in the critically ill. When both severe metabolic acidemia and moderate to severe acute kidney injury are observed, day 28 mortality is approximatively 55-60%. Severe acidemia has been shown to be a biomarker of severity but may also contribute by itself to outcome. Investigators recently performed a multiple center randomised clinical trial (BICARICU-1) that suggests that sodium bicarbonate infusion titrated to maintain the pH equal or more than 7.30 is associated with a higher survival rate (secondary endpoint) in patients presenting both severe metabolic acidemia and moderate to severe acute kidney injury patients. Whether sodium bicarbonate infusion may improve long term survival (Day 90, primary outcome) in these severe acute kidney injury patients is currently unknown.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJul 8, 2019
Enrollment StartOct 7, 2019
Primary CompletionDec 19, 2023
Study CompletionJun 17, 2024
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 7.0 years ago

Arms & Interventions

control groupno_intervention

The physicians will resuscitate the patients according to the current critical care medicine guidelines.

Sodium bicarbonate groupexperimental

Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion

Drug: Sodium bicarbonate infusion

Interventions

Sodium bicarbonate infusiondrug

Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion. Bicarbonate infusion recommendations will be as follow: a central line is recommended, infusion will be slow (125-250ml in 30 min, no intravenous push), careful surveillance of metabolic alkalosis, cardiogenic pulmonary edema, kalemia, natremia and calcemia. Repeated arterial blood gases will be suggested to monitor these critically ill patients and physicians will be reinformed of the potential side effects of sodium bicarbonate infusion.